Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Todd VanArsdale

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2015
Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer TreatmentTodd VanArsdale, Chris Boshoff, Kim T Arndt, et al.
Cell Death & Disease|November 16, 2019
Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinomaAnthony M Robinson, Richa Rathore, Nathan J Redlich, et al.
Oncogene|February 1, 2019
Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancerJoan Cao, Zhou Zhu, Hui Wang, et al.
Molecular Cancer Therapeutics|August 7, 2016
Spectrum and Degree of CDK Drug Interactions Predicts Clinical PerformancePing Chen, Nathan V Lee, Wenyue Hu, et al.
Nature|January 27, 2009
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemiaChen Zhao, Alan Chen, Catriona H Jamieson, et al.
Frontiers of Medicine|July 4, 2013
Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell lineDouglas D Fang, Joan Cao, Jitesh P Jani, et al.
Nature Communications|January 22, 2025
Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4/6 inhibitorsZhengyan Kan, Ji Wen, Vinicius Bonato, et al.
Cancer Cell|February 29, 2020
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic AdenocarcinomaBeatriz Salvador-Barbero, Mónica Álvarez-Fernández, Elisabet Zapatero-Solana, et al.
Cell Death and Differentiation|December 13, 2017
Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancerMónica Álvarez-Fernández, María Sanz-Flores, Belén Sanz-Castillo, et al.
Cancer Cell|October 13, 2020
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic AdenocarcinomaBeatriz Salvador-Barbero, Mónica Alvarez-Fernández, Elisabet Zapatero-Solana, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2015
Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer TreatmentTodd VanArsdale, Chris Boshoff, Kim T Arndt, et al.
Cell Death & Disease|November 16, 2019
Cisplatin exposure causes c-Myc-dependent resistance to CDK4/6 inhibition in HPV-negative head and neck squamous cell carcinomaAnthony M Robinson, Richa Rathore, Nathan J Redlich, et al.
Oncogene|February 1, 2019
Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancerJoan Cao, Zhou Zhu, Hui Wang, et al.
Molecular Cancer Therapeutics|August 7, 2016
Spectrum and Degree of CDK Drug Interactions Predicts Clinical PerformancePing Chen, Nathan V Lee, Wenyue Hu, et al.
Nature|January 27, 2009
Hedgehog signalling is essential for maintenance of cancer stem cells in myeloid leukaemiaChen Zhao, Alan Chen, Catriona H Jamieson, et al.
Frontiers of Medicine|July 4, 2013
Combined gemcitabine and CHK1 inhibitor treatment induces apoptosis resistance in cancer stem cell-like cells enriched with tumor spheroids from a non-small cell lung cancer cell lineDouglas D Fang, Joan Cao, Jitesh P Jani, et al.
Nature Communications|January 22, 2025
Real-world clinical multi-omics analyses reveal bifurcation of ER-independent and ER-dependent drug resistance to CDK4/6 inhibitorsZhengyan Kan, Ji Wen, Vinicius Bonato, et al.
Cancer Cell|February 29, 2020
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic AdenocarcinomaBeatriz Salvador-Barbero, Mónica Álvarez-Fernández, Elisabet Zapatero-Solana, et al.
Cell Death and Differentiation|December 13, 2017
Therapeutic relevance of the PP2A-B55 inhibitory kinase MASTL/Greatwall in breast cancerMónica Álvarez-Fernández, María Sanz-Flores, Belén Sanz-Castillo, et al.
Cancer Cell|October 13, 2020
CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic AdenocarcinomaBeatriz Salvador-Barbero, Mónica Alvarez-Fernández, Elisabet Zapatero-Solana, et al.
Pageof 4